Cover Image
市場調查報告書

次世代定序 (NGS) 的試樣製備市場

The Market for Sample Preparation for Next Generation Sequencing (NGS)

出版商 Kalorama Information 商品編碼 357810
出版日期 內容資訊 英文 185 Pages
訂單完成後即時交付
價格
Back to Top
次世代定序 (NGS) 的試樣製備市場 The Market for Sample Preparation for Next Generation Sequencing (NGS)
出版日期: 2016年04月27日 內容資訊: 英文 185 Pages
簡介

使用新一代定序的DNA、RNA定序成為生命科學研究的中心要素。可削減成本,以及急速改良成對用戶友善的東西。自動化,工作流程的合理化等技術創新讓準備過程更容易,且花的時間短。

本報告提供全球次世代定序 (NGS) 的試樣製備市場相關調查,市場收益與至2020年的成長率,各地區,各產品類型收益,加入此市場的主要企業的市場佔有率等簡介彙整。

第1章 摘要整理

第2章 趨勢

  • 對自動化、小型化的努力
  • 合併、收購、股權投資的增加
  • 小型定序器的迅速引進拓寬應用
  • 定序器平台的失速和中止
  • 顛覆性技術的可能性和穩定性
  • 定序器的銷售額氣勢漸增
  • 臨床的應用持續高成長
  • 中國是主要國家
  • 由於小企業的進入而增加的銷售契約
  • 法律規範趨勢不透明

第3章 產品

第4章 NGS試樣製備市場收益

  • 收益預測
  • 各地區收益
  • 各產品類型收益

第5章 競爭分析

  • 簡介
  • 定序器平台的穩定性
  • 市場佔有率
  • 小企業實現各種成功

第6章 智慧財產權與訴訟

第7章 交易

第8章 企業簡介

  • 10X Genomics
  • Agilent Technologies
  • F. Hoffmann-La Roche AG
  • Fluidigm
  • Illumina
  • New England Biolabs
  • Oxford Nanopore
  • Pacific Biosciences
  • Qiagen
  • Thermo Fisher Scientific

第9章 課題和策略性建議

圖表

目錄
Product Code: KLI5979660

DNA and RNA sequencing using next-generation sequencers is becoming a more central component of life science research. In addition to providing consistent decreases in cost per base, the technologies continue to rapidly improve and become more user-friendly. Automation, streamlining of workflows, and other innovations have gradually made the sample preparation process easier and less time-consuming. The Market for Sample Preparation for Next Generation Sequencing (NGS) focuses on the market for NGS sample preparation products, which includes the hardware and consumables. It discusses trends, challenges, strategies, companies, and products, and provides estimates of market share and revenue growth for the market, including:

  • NGS Sample Preparation Revenues and Growth Rate, 2015-2020
  • Revenues by Region, 2015 (N. America, Europe, Asia-Pacific, Rest-of-World)
  • Revenues by Product Type, 2015 (Enrichment, libr prep kits panels, etc.; Automation/ hardware; Nucleic acid extraction; Total)
  • NGS Sample Preparation Leading Company Revenues and Market Shares, 2015

The report highlights some of the major trends taking place in the market for library preparation and target enrichment for NGS. There are some areas of rapid change, but also many things that are staying relatively consistent. Some of the trends examined include:

  • Significant Efforts in Automation, Miniaturization
  • Rapid Adoption of Smaller Sequencers Driving Applications
  • Expanding Clinical Adoption Sustains High Growth
  • China Becoming Major Player in the Market
  • Regulatory Situation Unclear But Evolving Somewhat

The Market for Sample Preparation for NGS provides profiles of the leading companies in the NGS sample preparation and library preparation market, including:

  • 10X Genomics
  • Agilent Technologies
  • F. Hoffmann-La Roche AG
  • Fluidigm
  • Illumina
  • New England Biolabs
  • Oxford Nanopore
  • Pacific Biosciences
  • Qiagen
  • Thermo Fisher Scientific

The report provides detailed information about many of the current products available in the market for NGS sample preparation, including the hardware, reagents, kits, panels, and other consumables, such as:

  • DNA Extraction, Purification, and Isolation Products
  • RNA Extraction, Purification, and Isolation Products
  • Panels, Exome Kits, and Other Target Enrichment Products
  • DNA Library Construction/ Preparation Products
  • RNA-Seq, Transcriptome, and Gene Expression Products
  • Small RNA NGS Sample Preparation Products

The threats of disruptive technologies and regulatory constraints are ever-present factors, which are covered in detail. The report discusses some of the key challenges in the market for library preparation and target enrichment products, and provides some strategic recommendations that can be used to address the situations. Challenges reviewed include:

  • Unknown Effects of Closed Systems, Automation, Streamlining
  • Medical/ Scientific Discoveries Can Reduce Markets
  • Highly Concentrated Sequencer Market Increases Risks

Strategic recommendations examined include:

  • Expanding Market Requires Technical Support
  • Capitalizing on Stability While Preparing for Contingencies
  • Benefitting from Partnering or Communicating

The competitive situation, deals, and litigation are covered in respective chapters. The report was produced through a combination of primary research, secondary research, and internal databases, including SEC filings, product literature, corporate websites, conferences, journals, and trade publications.

Table of Contents

ONE: EXECUTIVE SUMMARY

  • Introduction
  • Product Introductions, Indications of Price Pressure
  • Stability in Sequencers Appears to Be Continuing
  • A Period of Rapid Adoption, But Lower Prices
  • High Likelihood of Longer-Term Challenges
  • Growth -- But Competitive, Concentrated, and Unpredictable
  • Background
  • Scope and Methodology
  • Applications and Definitions

TWO: TRENDS

  • Significant Efforts in Automation, Miniaturization
  • Mergers, Acquisitions, Equity Investments Increasing
  • Rapid Adoption of Smaller Sequencers Driving Applications
  • Expected Sequencer Platforms Stalled or Cancelled
  • Stability Despite Possibility of Disruptive Technologies
  • Sequencer Unit Sales Continue Momentum
  • Expanding Clinical Adoption Sustains High Growth
  • China Becoming Major Player in Market
  • Distribution Deals Increase as Smaller Companies Enter Market
  • Regulatory Situation Unclear But Evolving Somewhat

THREE: PRODUCTS

  • Recent Product Introductions
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012

FOUR: NGS SAMPLE PREPARATION MARKET REVENUES

  • Revenues Forecast
  • Revenues by Region
  • Revenues by Product Type
  • Illumina Consumables Revenues

FIVE: COMPETITIVE ANALYSIS

  • Introduction
  • Relative Stability in Sequencer Platforms
  • NGS Sample Preparation Market Shares
  • Smaller Companies Experiencing Mixed Success

SIX: INTELLECTUAL PROPERTY AND LITIGATION

  • Sequenom, Several NIPT Companies Fighting
  • Ariosa Diagnostics (Roche) Files Suit against Sequenom
  • Natera Sues Sequenom; Sequenom Sues Natera
  • Verinata Health and Stanford File Against Sequenom
  • Verinata Health Against Ariosa and LabCorp
  • Illumina Sues Ariosa Diagnostics For NIPT Test
  • Illumina Sues Premaitha Health for NIPT Test
  • Illumina Sues Premaitha and Ariosa Partners
  • Sequenom and Illumina Settle and Pool Patents
  • Sequenom Petitions Supreme Court
  • Illumina's Conflicts With Oxford Nanopore
  • Enzo Biochem Brings Suit against Numerous Companies
  • 454 (Roche) Sues Ion Torrent (Thermo Fisher)
  • RainDance Technologies Sues 10X Genomics
  • 10X Genomics' Dispute with Bio-Rad
  • Sequenom Shareholder Sues Over Price “Capping”
  • Class Action Shareholder Lawsuit Filed Against Pacific Biosciences
  • Helicos' Patent Infringement Suit against PacBio, Life Technologies, and Illumina
  • Illumina's Two Lawsuits against Complete Genomics for Infringement
  • Life Technologies and Illumina Dispute Over Amplification on Solid Surfaces
  • Life Technologies Files Infringement Suit against Promega
  • Enzo Biochem Disputes Sequencing Patents
  • Azco Biotech Sues Qiagen and Intelligent Bio-Systems
  • Intelligent Bio-Systems (Qiagen) and Columbia University Sue Illumina for
  • Infringement
  • LabCorp's Esoterix Sues Life Technologies
  • Genetic Technologies Sues Several Firms for Infringement of Haplotype
  • Determination Technique
  • Illumina Sues Life Technologies Over Ion Torrent Systems
  • Affymetrix Dismisses Suit against Pacific Biosciences and Former Employees
  • Life Technologies Defeats VisiGen Stakeholders after Arbitration
  • Catalyst Assets Sues Life Technologies for Infringement
  • Patent Interference between Life Technologies and Pacific Biosciences
  • LadaTech Sues Illumina Over DNA Amplification Patent
  • Illumina Files ‘841 Patent Infringement Suit against Affymetrix
  • Affymetrix and Illumina Settle Case Over ‘243, ‘432, ‘531, ‘365, and ‘716
  • Applied Biosystems and Illumina Claims and Counter-Claims Over Sequencingby-
  • Ligation Both Unsuccessful

SEVEN: DEALS

EIGHT: CORPORATE PROFILES

  • 10X Genomics
  • Agilent Technologies
  • F. Hoffmann-La Roche AG
  • Fluidigm
  • Illumina
  • New England Biolabs
  • Oxford Nanopore
  • Pacific Biosciences
  • Qiagen
  • Thermo Fisher Scientific

NINE: CHALLENGES AND STRATEGIC RECOMMENDATIONS

  • Challenges
  • Unknown Effects of Closed Systems, Automation, Streamlining
  • Medical/ Scientific Discoveries Can Reduce Markets
  • Highly Concentrated Sequencer Market Increases Risks
  • Dropping Sequencing Costs Create Complex Situations
  • Sample Preparation Customer Loyalty Lacking
  • Shortcomings and Pitfalls Require Solutions
  • Low Barriers Cause Increased Competition Short-Term
  • Uncertainty and Debate with LDT Regulation and Adoption
  • Complexity and Difficulty Restrains Broad Adoption
  • Many Labs Opting for Services over Purchasing Sequencers
  • Strategic Recommendations
  • Expanding Market Requires Technical Support
  • Reduce Bias, Compensate, or Characterize It
  • Capitalize on Stability While Preparing for Contingencies
  • Address or Anticipate Price Pressure
  • Benefit from Partnering or Communicating
  • Complementary Products, Other Ways to Hedge
  • Use Services for Visibility and Monetization
  • Address or Ease Data Analysis Challenges
  • Anticipate or Position for Global Adoption

LIST OF EXHIBITS

THREE: PRODUCTS

  • Table 3-1: DNA Extraction, Purification, and Isolation Products
  • Table 3-2: RNA Extraction, Purification, and Isolation Products
  • Table 3-3: Panels, Exome Kits, and Other Target Enrichment Products
  • Table 3-4: DNA Library Construction/ Preparation Products
  • Table 3-5: RNA-Seq, Transcriptome, and Gene Expression Products
  • Table 3-6: Small RNA NGS Sample Preparation Products
  • Table 3-7: ChIP-Seq Products
  • Table 3-8: Methylation and Other Epigenetics Products
  • Table 3-9: Single-Cell NGS Products
  • Table 3-10: Synthetic/ Novel Long Read NGS Technologies/ Products
  • Table 3-11: Library Quantitation / Quality Control Products
  • Table 3-12: Shearing and Fragmentation Products
  • Table 3-13: Fragment/ Size Selection Products
  • Table 3-14: Automated Systems, Liquid Handlers, Other Hardware

FOUR: NGS SAMPLE PREPARATION MARKET REVENUES

  • Figure 4-1: Cost of Sequencing a Genome, 1990-2020
  • Table 4-1: NGS Sample Preparation Revenues and Growth Rate, 2015-2020
  • Figure 4-2: NGS Sample Preparation Revenues, 2015-2020 ($M)
  • Figure 4-3: NGS Sample Preparation Growth Rate, 2015-2020 ($M)
  • Table 4-2: Revenues by Region, 2015 (N. America, Europe, Asia-Pacific, Rest-of- World)
  • Figure 4-4: Revenues by Region, 2015 (N. America, Europe, Asia-Pacific, Rest-of- World)
  • Table 4-3: Revenues by Product Type, 2015 (Enrichment, libr prep kits panels, etc.; Automation/ hardware; Nucleic acid extraction; Total)
  • Figure 4-5: Revenues by General Product Type, 2015 (Enrichment, libr prep kits panels, etc.; Automation/ hardware; Nucleic acid extraction; Total)
  • Table 4-4: Illumina Quarterly Consumables Revenues (2012-2015) (sequencing consumables, total consumables)
  • Figure 4-6: Illumina Quarterly Consumables Revenues (2012-2015) (sequencing consumables, total consumables)
  • Table 4-5: Illumina Annual Consumables Revenues (2012-2015) (sequencing consumables, total consumables, sequencing share)
  • Table 4-6: Illumina Consumables Growth Rates (2013-2015) (sequencing consumables, total consumables)
  • Figure 4-7: Illumina 2012 Sequencing Consumables Share (other consumables, sequencing consumables)
  • Figure 4-8: Illumina 2015 Sequencing Consumables Share (other consumables, sequencing consumables)

FIVE: COMPETITIVE ANALYSIS

  • Table 5-1: NGS Sample Preparation Leading Company Revenues and Market Shares, 2015
  • Figure 5-1: NGS Sample Preparation Leading Company Market Shares, 2015

SEVEN: DEALS

  • Table 7-1: Significant Collaborations in Recent Years (2010-2016)
Back to Top